Trials / Completed
CompletedNCT02402452
Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment
A Phase 1 Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-9857 in Subjects With Normal Renal Function and Severe Renal Impairment
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years – 79 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of this study is to evaluate the pharmacokinetics, safety, and tolerability of voxilaprevir (formerly GS-9857) in participants with severe renal impairment and matched healthy control participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Voxilaprevir | 100 mg tablet administered orally |
Timeline
- Start date
- 2015-05-05
- Primary completion
- 2015-09-28
- Completion
- 2015-09-28
- First posted
- 2015-03-30
- Last updated
- 2020-03-20
- Results posted
- 2020-03-20
Locations
4 sites across 3 countries: United States, Germany, New Zealand
Source: ClinicalTrials.gov record NCT02402452. Inclusion in this directory is not an endorsement.